en.unionpedia.org

Cancer Drugs Fund, the Glossary

The Cancer Drugs Fund (CDF) was introduced in England in 2011.^[1]

28 relations: Andy Burnham, Annals of Oncology, Bevacizumab, Cancer in the United Kingdom, Conservative–Liberal Democrat coalition agreement, Financial Times, Health economics, Incremental cost-effectiveness ratio, James Le Fanu, Karl Claxton, King's College London, Merck & Co., National Audit Office (United Kingdom), National Health Service (England), National Institute for Health and Care Excellence, Pembrolizumab, Pharmaceutical industry, Public Accounts Committee (United Kingdom), Quality-adjusted life year, Regorafenib, Roche, Senedd, Strategic health authority, The Daily Telegraph, Trastuzumab emtansine, University of York, Value-based pricing, Welsh Labour.
Chemotherapy

Andy Burnham

Andrew Murray Burnham (born 7 January 1970) is a British politician who has served as Mayor of Greater Manchester since 2017.

See Cancer Drugs Fund and Andy Burnham

Annals of Oncology

The Annals of Oncology is a peer-reviewed medical journal of oncology, published by Elsevier.

See Cancer Drugs Fund and Annals of Oncology

Bevacizumab

Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease.

See Cancer Drugs Fund and Bevacizumab

Cancer in the United Kingdom

The passing of the Cancer Act 1939 marked the political significance of cancer treatment.

See Cancer Drugs Fund and Cancer in the United Kingdom

Conservative–Liberal Democrat coalition agreement

The Conservative–Liberal Democrat coalition agreement (officially known as The Coalition: Our Programme for Government) was a policy document drawn up following the 2010 general election in the United Kingdom.

See Cancer Drugs Fund and Conservative–Liberal Democrat coalition agreement

Financial Times

The Financial Times (FT) is a British daily newspaper printed in broadsheet and also published digitally that focuses on business and economic current affairs.

See Cancer Drugs Fund and Financial Times

Health economics

Health economics is a branch of economics concerned with issues related to efficiency, effectiveness, value and behavior in the production and consumption of health and healthcare.

See Cancer Drugs Fund and Health economics

Incremental cost-effectiveness ratio

The incremental cost-effectiveness ratio (ICER) is a statistic used in cost-effectiveness analysis to summarise the cost-effectiveness of a health care intervention.

See Cancer Drugs Fund and Incremental cost-effectiveness ratio

James Le Fanu

James Le Fanu (born 1950) is a British retired general practitioner, journalist and author, best known for his weekly columns in the Daily and Sunday Telegraph.

See Cancer Drugs Fund and James Le Fanu

Karl Claxton

Professor Karl Claxton (born 1 March 1967) is a health economist at the University of York.

See Cancer Drugs Fund and Karl Claxton

King's College London

King's College London (informally King's or KCL) is a public research university located in London, England.

See Cancer Drugs Fund and King's College London

Merck & Co.

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm.

See Cancer Drugs Fund and Merck & Co.

National Audit Office (United Kingdom)

The National Audit Office (NAO) is an independent Parliamentary body in the United Kingdom which is responsible for auditing central government departments, government agencies and non-departmental public bodies.

See Cancer Drugs Fund and National Audit Office (United Kingdom)

National Health Service (England)

The National Health Service (NHS) is the publicly funded healthcare system in England, and one of the four National Health Service systems in the United Kingdom.

See Cancer Drugs Fund and National Health Service (England)

National Institute for Health and Care Excellence

The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body, in England, of the Department of Health and Social Care, that publishes guidelines in four areas.

See Cancer Drugs Fund and National Institute for Health and Care Excellence

Pembrolizumab

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.

See Cancer Drugs Fund and Pembrolizumab

Pharmaceutical industry

The pharmaceutical industry is an industry involved in medicine that discovers, develops, produces, and markets pharmaceutical goods for use as drugs that function by being administered to (or self-administered by) patients using such medications with the goal of curing and/or preventing disease (as well as possibly alleviating symptoms of illness and/or injury).

See Cancer Drugs Fund and Pharmaceutical industry

Public Accounts Committee (United Kingdom)

The Committee of Public Accounts is a select committee of the British House of Commons.

See Cancer Drugs Fund and Public Accounts Committee (United Kingdom)

Quality-adjusted life year

The quality-adjusted life year (QALY) is a generic measure of disease burden, including both the quality and the quantity of life lived.

See Cancer Drugs Fund and Quality-adjusted life year

Regorafenib

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK).

See Cancer Drugs Fund and Regorafenib